vs

Side-by-side financial comparison of GRACO INC (GGG) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $593.2M, roughly 1.0× GRACO INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 22.3%, a 12.1% gap on every dollar of revenue. On growth, GRACO INC posted the faster year-over-year revenue change (8.1% vs 4.8%). Over the past eight quarters, GRACO INC's revenue compounded faster (9.8% CAGR vs 4.6%).

Graco Inc. is an American industrial company that specializes in the development and manufacturing of fluid-handling systems and products. The company is headquartered in Minneapolis, Minnesota, and markets its products to customers worldwide.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

GGG vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.0× larger
RPRX
$622.0M
$593.2M
GGG
Growing faster (revenue YoY)
GGG
GGG
+3.3% gap
GGG
8.1%
4.8%
RPRX
Higher net margin
RPRX
RPRX
12.1% more per $
RPRX
34.4%
22.3%
GGG
Faster 2-yr revenue CAGR
GGG
GGG
Annualised
GGG
9.8%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GGG
GGG
RPRX
RPRX
Revenue
$593.2M
$622.0M
Net Profit
$132.5M
$214.2M
Gross Margin
51.7%
Operating Margin
26.7%
62.4%
Net Margin
22.3%
34.4%
Revenue YoY
8.1%
4.8%
Net Profit YoY
21.9%
2.9%
EPS (diluted)
$0.78
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GGG
GGG
RPRX
RPRX
Q4 25
$593.2M
$622.0M
Q3 25
$543.4M
$609.3M
Q2 25
$571.8M
$578.7M
Q1 25
$528.3M
$568.2M
Q4 24
$548.7M
$593.6M
Q3 24
$519.2M
$564.7M
Q2 24
$553.2M
$537.3M
Q1 24
$492.2M
$568.0M
Net Profit
GGG
GGG
RPRX
RPRX
Q4 25
$132.5M
$214.2M
Q3 25
$137.6M
$288.2M
Q2 25
$127.6M
$30.2M
Q1 25
$124.1M
$238.3M
Q4 24
$108.7M
$208.2M
Q3 24
$122.2M
$544.0M
Q2 24
$133.0M
$102.0M
Q1 24
$122.2M
$4.8M
Gross Margin
GGG
GGG
RPRX
RPRX
Q4 25
51.7%
Q3 25
53.2%
Q2 25
52.4%
Q1 25
52.6%
Q4 24
50.9%
Q3 24
53.2%
Q2 24
54.4%
Q1 24
54.1%
Operating Margin
GGG
GGG
RPRX
RPRX
Q4 25
26.7%
62.4%
Q3 25
30.3%
70.1%
Q2 25
27.5%
36.3%
Q1 25
27.3%
94.0%
Q4 24
23.7%
60.9%
Q3 24
28.1%
Q2 24
29.2%
50.2%
Q1 24
27.0%
-13.0%
Net Margin
GGG
GGG
RPRX
RPRX
Q4 25
22.3%
34.4%
Q3 25
25.3%
47.3%
Q2 25
22.3%
5.2%
Q1 25
23.5%
41.9%
Q4 24
19.8%
35.1%
Q3 24
23.5%
96.3%
Q2 24
24.0%
19.0%
Q1 24
24.8%
0.8%
EPS (diluted)
GGG
GGG
RPRX
RPRX
Q4 25
$0.78
$0.49
Q3 25
$0.82
$0.67
Q2 25
$0.76
$0.07
Q1 25
$0.72
$0.55
Q4 24
$0.63
$0.46
Q3 24
$0.71
$1.21
Q2 24
$0.77
$0.23
Q1 24
$0.71
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GGG
GGG
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$624.1M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$2.7B
$9.7B
Total Assets
$3.3B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GGG
GGG
RPRX
RPRX
Q4 25
$624.1M
$618.7M
Q3 25
$618.7M
$938.9M
Q2 25
$534.9M
$631.9M
Q1 25
$536.1M
$1.1B
Q4 24
$675.3M
$929.0M
Q3 24
$764.5M
$950.1M
Q2 24
$666.0M
$1.8B
Q1 24
$622.7M
$843.0M
Total Debt
GGG
GGG
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
GGG
GGG
RPRX
RPRX
Q4 25
$2.7B
$9.7B
Q3 25
$2.6B
$9.6B
Q2 25
$2.5B
$9.5B
Q1 25
$2.5B
$9.8B
Q4 24
$2.6B
$10.3B
Q3 24
$2.5B
$10.3B
Q2 24
$2.4B
$9.8B
Q1 24
$2.3B
$9.9B
Total Assets
GGG
GGG
RPRX
RPRX
Q4 25
$3.3B
$19.6B
Q3 25
$3.2B
$19.3B
Q2 25
$3.0B
$18.3B
Q1 25
$3.0B
$17.6B
Q4 24
$3.1B
$18.2B
Q3 24
$3.0B
$18.0B
Q2 24
$2.9B
$17.7B
Q1 24
$2.8B
$16.1B
Debt / Equity
GGG
GGG
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GGG
GGG
RPRX
RPRX
Operating Cash FlowLast quarter
$196.3M
$827.1M
Free Cash FlowOCF − Capex
$184.3M
FCF MarginFCF / Revenue
31.1%
Capex IntensityCapex / Revenue
2.0%
Cash ConversionOCF / Net Profit
1.48×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$637.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GGG
GGG
RPRX
RPRX
Q4 25
$196.3M
$827.1M
Q3 25
$179.2M
$702.6M
Q2 25
$182.7M
$364.0M
Q1 25
$125.4M
$596.1M
Q4 24
$185.2M
$742.5M
Q3 24
$178.6M
$703.6M
Q2 24
$139.0M
$658.2M
Q1 24
$118.9M
$664.6M
Free Cash Flow
GGG
GGG
RPRX
RPRX
Q4 25
$184.3M
Q3 25
$175.7M
Q2 25
$163.1M
Q1 25
$114.8M
Q4 24
$171.3M
Q3 24
$159.2M
Q2 24
$102.7M
Q1 24
$81.7M
FCF Margin
GGG
GGG
RPRX
RPRX
Q4 25
31.1%
Q3 25
32.3%
Q2 25
28.5%
Q1 25
21.7%
Q4 24
31.2%
Q3 24
30.7%
Q2 24
18.6%
Q1 24
16.6%
Capex Intensity
GGG
GGG
RPRX
RPRX
Q4 25
2.0%
Q3 25
0.6%
Q2 25
3.4%
Q1 25
2.0%
Q4 24
2.5%
Q3 24
3.7%
Q2 24
6.6%
Q1 24
7.6%
Cash Conversion
GGG
GGG
RPRX
RPRX
Q4 25
1.48×
3.86×
Q3 25
1.30×
2.44×
Q2 25
1.43×
12.06×
Q1 25
1.01×
2.50×
Q4 24
1.70×
3.57×
Q3 24
1.46×
1.29×
Q2 24
1.05×
6.45×
Q1 24
0.97×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GGG
GGG

Industrial$284.3M48%
Contractor$265.5M45%
Other$43.4M7%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons